USP10 modulates the SKP2/Bcr-Abl axis via stabilizing SKP2 in chronic myeloid leukemia

a Cell viability of CML cells post Imatinib (IM) treatment for the indicated times. b Western blot analysis for the indicated proteins in CML cells exposed to IM for 24？h. c Western blot analysis and Co-IP analysis for the indicated proteins in CML cells. d, e Western blot assay for the indicated proteins in CML cells exposed to specific inhibitor of SKP2 (SKP2-C25) or stably expressing SKP2 shRNA. f, g Cell viability of CML cells exposed to SKP2-C25 for 48？h or stably expressing SKP2 shRNA/control shRNA for 24, 48, and 72？h. Error bars correspond to 95% confidence intervals of three independent experiments. *P？<？0.05 versus each vehicle control. h Western blot and Co-IP assays to detect K63/K48-linked ubiquitination of Bcr-Abl of KBM5-T315I cells post SKP2 shRNA/SKP2-C25 treatmen